insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

MDLN · Medline Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · MDLN

Sign in to download
AnnualQuarterly

Income Statement

Line itemQ1 '26Q4 '25Q4 '24Q4 '23Q4 '22
Revenue$6.64B----
Cost of Revenue$4.82B----
Gross Profit$1.82B----
R&D-----
SG&A$1.07B----
Total Operating Expenses$1.25B----
D&A$247.00M----
Operating Income$571.00M----
Interest Expense$244.00M----
Income Tax$16.00M----
Net Income$319.00M----
EPS - Basic$0.16----
EPS - Diluted$0.16----

Balance Sheet

Line itemQ1 '26Q4 '25Q4 '24Q4 '23Q4 '22
Cash & Equivalents$2.24B$1.94B$199.00M$1.58B$399.00M
Accounts Receivable$3.67B$3.53B$3.22B--
Inventory$4.81B$4.77B$4.46B--
Accounts Payable$932.00M$961.00M$869.00M--
Current Assets$11.18B$10.68B$8.27B--
Total Assets$39.01B$38.48B$35.98B--
Current Liabilities$2.54B$2.49B$2.44B--
Long-term Debt$12.49B$12.48B$16.42B--
Total Liabilities$19.66B$19.20B$19.45B--
Stockholders' Equity$11.27B$10.74B---
Retained Earnings$122.00M($7.00M)---

Cash Flow

Line itemQ1 '26Q4 '25Q4 '24Q4 '23Q4 '22
Operating Cash Flow$682.00M----
Investing Cash Flow($92.00M)----
Financing Cash Flow($9.00M)----
CapEx$98.00M----
Free Cash Flow$584.00M----

Ratios

MetricQ1 '26Q4 '25Q4 '24Q4 '23Q4 '22
Profitability
Gross margin27.5%----
Operating margin8.6%----
EBITDA margin12.3%----
Net margin4.8%----
Free cash flow margin8.8%----
FCF / Net income1.83----
R&D / Revenue-----
SG&A / Revenue16.1%----
Effective tax rate4.8%----
Return on assets0.8%----
Return on equity2.8%----
Return on invested capital2.3%----
Liquidity
Current ratio4.414.293.39--
Quick ratio2.512.371.56--
Cash ratio0.880.780.08--
Leverage
Debt / Equity1.111.16---
Debt / Assets0.320.320.46--
Debt / EBITDA15.28----
Interest coverage2.3x----
Equity multiplier3.463.58---
Liabilities / Assets0.500.500.54--
Efficiency
Asset turnover0.17----
Inventory turnover1.00----
Days sales outstanding202d----
Days inventory outstanding364d----
Days payable outstanding71d----
Cash conversion cycle495d----
Valuation
P / E258.5x----
P / B3.0x----
P / S5.1x----
EV / EBITDA54.2x----
Growth
Revenue growth (YoY)-----
Revenue CAGR (3y)-----
Revenue CAGR (5y)-----
Gross profit growth (YoY)-----
Operating income growth (YoY)-----
Net income growth (YoY)-----
EPS growth (YoY)-----
EPS CAGR (3y)-----
EPS CAGR (5y)-----
FCF growth (YoY)-----
FCF CAGR (5y)-----
Book value growth (YoY)-----

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2025-12-31.

Business segments

$28.43B total
Supply Chain Solutions Segment$14.71B · 51.7%
Medline Brand Segment$13.72B · 48.3%

Product / service

$40.20B total
Acute Care$19.51B · 48.5%
Non Acute Care$6.97B · 17.3%
Front Line Care$6.51B · 16.2%
Surgical Solutions$6.17B · 15.3%
Laboratory And Diagnostics$1.04B · 2.6%

Geographic

$28.43B total
US$26.48B · 93.1%
Non Us$1.95B · 6.9%

Peer comparison

Same SIC group: Surgical & Medical Instruments & Apparatus

CompanyRevenue (last FY)Net marginROE
BSX$20.07B14.4%12.0%
LMAT$249.60M23.1%14.7%
TNDM$1.01B-20.2%-131.9%
SYK$25.12B12.9%14.5%
MMM$24.95B13.0%69.1%

Comparing Medline Inc. against the 5 most active filers in the same SIC group.